Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance.
Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance.
复制标题
DOI：
10.3390/cancers13184634
复制
发表时间：
2021-09-15
期刊：
影响因子：
5.2
通讯作者：
Theocharis S
中科院分区：
文献类型：
--
作者：
Goutas D;Goutas N;Theocharis S
With pancreatic cancer incidence constantly rising, constituting one of the most lethal type of cancers worldwide, the need for discovering novel therapeutic targets and approaches becomes of the utmost importance. Meanwhile, modern eating habits, hyperadiposity, mutational burden affecting core signaling pathways and the unique tumor microenvironment of pancreatic cancer tissues intermingle and form a disease that is lethal and hard to treat. The importance of HuR in pancreatic cancer has repeatedly been observed and represents a key molecule in pancreatic carcinogenesis and chemoresistance. Therefore, creating and obtaining new therapeutic skills against HuR protein could prove to be the answer to pancreatic cancer therapy. Pancreatic cancer is set to become the most lethal and common type of cancer worldwide. This is partly attributed to the mutational burden that affects core signaling pathways and the crosstalk of tumor cells with their surrounding microenvironment, but it is also due to modern eating habits. Hyperadiposity along with the constant rise in metabolic syndrome’s incidence contribute to a state of metaflammation that impacts immune cells and causes them to shift towards an immunosuppressive phenotype that, ultimately, allows tumor cells to evade immune control. Unfortunately, among the conventional therapeutic modalities and the novel therapeutic agents introduced, pancreatic cancer still holds one of the lowest response rates to therapy. Human antigen R (HuR), an RNA binding protein (RBP), has been repeatedly found to be implicated in pancreatic carcinogenesis and chemotherapy resistance through the posttranscriptional binding and regulation of mRNA target genes. Additionally, its overexpression has been linked to adverse clinical outcomes, in terms of tumor grade, stage, lymph node status and metastasis. These properties suggest the prospective role that HuR’s therapeutic targeting can play in facilitating pancreatic neoplasia and could provide the means to overcome chemoresistance.
登录
查看更多内容
影响因子：
8
作者：
Blanco FF;Jimbo M;Wulfkuhle J;Gallagher I;Deng J;Enyenihi L;Meisner-Kober N;Londin E;Rigoutsos I;Sawicki JA;Risbud MV;Witkiewicz AK;McCue PA;Jiang W;Rui H;Yeo CJ;Petricoin E;Winter JM;Brody JR
通讯作者：
Brody JR
影响因子：
--
作者：
Jimbo M;Blanco FF;Huang YH;Telonis AG;Screnci BA;Cosma GL;Alexeev V;Gonye GE;Yeo CJ;Sawicki JA;Winter JM;Brody JR
通讯作者：
Brody JR
影响因子：
11.2
作者：
Chang, Qing;Jurisica, Igor;Hedley, David W.
通讯作者：
Hedley, David W.
影响因子：
6.2
作者：
Büchler, P;Reber, HA;Hines, OJ
通讯作者：
Hines, OJ
DOI：
10.1016/j.nano.2017.11.010
发表时间：
2018-03
期刊：
Nanomedicine : nanotechnology, biology, and medicine
影响因子：
--
作者：
Amreddy N;Babu A;Panneerselvam J;Srivastava A;Muralidharan R;Chen A;Zhao YD;Munshi A;Ramesh R
通讯作者：
Ramesh R